10181790Enabling reproducible and scalable AAV production through advanced metabolomic analysis of HEK293 suspension cellsActiveGrant for R&DInnovate UKThis project will pioneer a new approach to making viral vectors --- the essential building blocks for many advanced therapies --- by combining precision small-scale manufacturing with world-class molecular measurement. It brings together BiologIC Technologies, developer of the Qudos personal biomanufacturing system, and the National Measurement Laboratory (NML). BiologIC's Qudos platform enables scientists to run high-performance biomanufacturing processes in a compact, automated system that fits on a benchtop. This "personal manufacturing" category represents a major shift in how biological medicines can be developed and manufactured, giving individual researchers or small teams the power of a traditional factory in their own hands. In this project, BiologIC will use Qudos to grow and purify viral vectors at small volumes, replicating the essential steps of industrial manufacturing in a controlled and data-rich environment. NML will apply advanced molecular analysis to measure the quality and integrity of the viral vectors produced, with a view to meeting the highest scientific and regulatory standards. By combining BiologIC's manufacturing capabilities with NML's precision measurement expertise, the partners will create a feedback loop that allows rapid optimisation and quality improvement of the production process. The result will be a powerful new way to accelerate the development of advanced therapies, making high-quality viral vector manufacture more consistent, accessible and sustainable. This project demonstrates how personal manufacturing systems like Qudos can transform the way medicines are discovered, developed and brought to patients.